BRPI0722070A2 - Inibidores de poli(adp-ribose)polimerase - Google Patents

Inibidores de poli(adp-ribose)polimerase

Info

Publication number
BRPI0722070A2
BRPI0722070A2 BRPI0722070-7A2A BRPI0722070A BRPI0722070A2 BR PI0722070 A2 BRPI0722070 A2 BR PI0722070A2 BR PI0722070 A BRPI0722070 A BR PI0722070A BR PI0722070 A2 BRPI0722070 A2 BR PI0722070A2
Authority
BR
Brazil
Prior art keywords
adp
ribose
poly
polymerase inhibitors
polymerase
Prior art date
Application number
BRPI0722070-7A2A
Other languages
English (en)
Inventor
Viraj B Gandhi
Vincent L Giranda
Jianchun Gong
Thomas D Penning
Gui-Dong Zhu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0722070(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0722070A2 publication Critical patent/BRPI0722070A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0722070-7A2A 2006-12-28 2007-12-20 Inibidores de poli(adp-ribose)polimerase BRPI0722070A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88231706P 2006-12-28 2006-12-28
PCT/US2007/088319 WO2008083027A1 (en) 2006-12-28 2007-12-20 Inhibitors of poly(adp-ribose)polymerase

Publications (1)

Publication Number Publication Date
BRPI0722070A2 true BRPI0722070A2 (pt) 2014-04-08

Family

ID=39584870

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0722070-7A2A BRPI0722070A2 (pt) 2006-12-28 2007-12-20 Inibidores de poli(adp-ribose)polimerase

Country Status (31)

Country Link
US (1) US20080161280A1 (pt)
EP (2) EP2698062B1 (pt)
JP (2) JP5523837B2 (pt)
KR (2) KR101491998B1 (pt)
CN (2) CN101641014B (pt)
AU (1) AU2007340020B2 (pt)
BR (1) BRPI0722070A2 (pt)
CA (1) CA2672868C (pt)
CO (1) CO6220961A2 (pt)
CR (1) CR10901A (pt)
DK (2) DK2698062T3 (pt)
DO (1) DOP2009000159A (pt)
EC (1) ECSP099530A (pt)
ES (2) ES2548353T3 (pt)
GT (1) GT200900182A (pt)
HR (1) HRP20140115T1 (pt)
HU (1) HUE027641T2 (pt)
MX (2) MX347085B (pt)
MY (2) MY165570A (pt)
NO (1) NO20092698L (pt)
NZ (2) NZ577348A (pt)
PH (1) PH12012501544A1 (pt)
PL (2) PL2120579T3 (pt)
PT (2) PT2120579E (pt)
RS (1) RS53196B (pt)
RU (1) RU2455286C2 (pt)
SG (2) SG2014013411A (pt)
SI (2) SI2698062T1 (pt)
TW (1) TWI429438B (pt)
UA (1) UA97506C2 (pt)
WO (1) WO2008083027A1 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
WO2009034326A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｐａｒｐ阻害剤としてのピリダジノン誘導体
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
ES2551557T3 (es) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
EP2389379A1 (en) 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2012016876A1 (en) * 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
RU2013150102A (ru) 2011-04-11 2015-05-20 Эббви Инк. Ингибиторы parp для лечения cipn
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
TWI548637B (zh) * 2011-07-26 2016-09-11 江蘇豪森藥業集團有限公司 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
BR112014003981A2 (pt) 2011-08-23 2017-03-07 Endo Pharmaceuticals Inc compostos de pirimido-piridazinona e seu uso
US9365562B2 (en) 2011-10-06 2016-06-14 Merck Sharp & Dohme Corp. 1,3 substituted azetidine PDE10 inhibitors
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
MX2015006780A (es) * 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
EP3481816B1 (en) * 2016-07-07 2020-06-24 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
EP3997075A1 (de) * 2019-07-10 2022-05-18 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-(phenylimino)-1,3-thiazolidin-4-onen
US20220298141A1 (en) * 2019-08-21 2022-09-22 Kalvista Pharmaceuticals Limited Enzyme inhibitors
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮
KR102913343B1 (ko) 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형
WO2021214502A1 (en) 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
US12059419B2 (en) * 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US20240150345A1 (en) * 2021-01-22 2024-05-09 Hibercell, Inc. Gcn2 modulating compounds and uses thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
US20240287022A1 (en) * 2021-06-28 2024-08-29 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives
KR100957516B1 (ko) * 2001-08-15 2010-05-14 이코스 코포레이션 2ｈ-프탈라진-1-온 및 이것의 사용 방법
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
KR100663147B1 (ko) * 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
AU2003255149A1 (en) * 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2006003147A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
KR20100015857A (ko) * 2007-04-23 2010-02-12 노파르티스 아게 Ｓ1ｐ 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체
WO2009034326A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
ATE525370T1 (de) * 2007-10-11 2011-10-15 Glaxo Group Ltd Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten

Also Published As

Publication number Publication date
RU2455286C2 (ru) 2012-07-10
ES2548353T3 (es) 2015-10-15
DK2120579T3 (da) 2014-02-03
EP2698062A1 (en) 2014-02-19
RS53196B (sr) 2014-06-30
PT2120579E (pt) 2014-02-17
ECSP099530A (es) 2009-08-28
NZ598352A (en) 2013-08-30
DK2698062T3 (en) 2015-09-14
UA97506C2 (xx) 2012-02-27
MY190838A (en) 2022-05-12
GT200900182A (es) 2010-02-19
US20080161280A1 (en) 2008-07-03
CR10901A (es) 2009-07-23
TWI429438B (zh) 2014-03-11
JP2014001209A (ja) 2014-01-09
EP2120579A1 (en) 2009-11-25
CN101641014B (zh) 2013-12-18
EP2120579A4 (en) 2011-04-27
HK1194922A1 (en) 2014-10-31
SG2014013411A (en) 2014-07-30
JP5523837B2 (ja) 2014-06-18
TW200840579A (en) 2008-10-16
SI2120579T1 (sl) 2014-03-31
CN103690542B (zh) 2015-11-18
PL2120579T3 (pl) 2014-04-30
MY165570A (en) 2018-04-05
MX2009007051A (es) 2009-07-10
WO2008083027A1 (en) 2008-07-10
SI2698062T1 (sl) 2015-12-31
HRP20140115T1 (hr) 2014-03-14
PL2698062T3 (pl) 2015-12-31
KR101449436B1 (ko) 2014-10-14
KR101491998B1 (ko) 2015-02-10
EP2698062B1 (en) 2015-06-24
CA2672868A1 (en) 2008-07-10
HUE027641T2 (en) 2016-11-28
PT2698062E (pt) 2015-10-19
RU2009128984A (ru) 2011-02-10
KR20140056395A (ko) 2014-05-09
NO20092698L (no) 2009-09-28
CA2672868C (en) 2015-11-24
CO6220961A2 (es) 2010-11-19
CN101641014A (zh) 2010-02-03
AU2007340020A1 (en) 2008-07-10
MX347085B (es) 2017-04-06
PH12012501544A1 (en) 2024-06-03
JP2010514785A (ja) 2010-05-06
KR20090094116A (ko) 2009-09-03
AU2007340020B2 (en) 2013-06-20
DOP2009000159A (es) 2015-11-30
SG193664A1 (en) 2013-10-30
ES2442496T3 (es) 2014-02-11
EP2120579B1 (en) 2013-11-13
NZ577348A (en) 2012-04-27
CN103690542A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
LTPA2019522I1 (lt) Poli(ADP-ribozės)polimerazės (PARP) dihidropiridoftalazinono inhibitoriai
LTPA2018009I1 (lt) Amidu pakeisti indazolai, kaip poli(ADP-ribozės)polimerazės (PARP) inhibitoriai
BRPI1007358A2 (pt) inibidores de poli (adp-ribose) polimerase (parp)
SG2014013411A (en) Inhibitors of poly(adp-ribose)polymerase
DK2069312T3 (da) Pyridazinonderivater
ES2527265T8 (es) Consola
BRPI0718796A2 (pt) Nucleotídeo
DE602007001549D1 (de) Substrathaltevorrichtung
EP2043672A4 (en) SELECTIVE INHIBITORS OF CASPASES
EP2115033A4 (en) POLYURETHANE
DE112007003149A5 (de) Spannfutter
DE602007009224D1 (de) R-cellular-systemen
EP1981070A4 (en) POLISHING CUSHIONS FOR CHEMICAL-MECHANICAL POLISHING
DE112006004211A5 (de) Bohrfutter
DE502006005977D1 (de) Baugruppenträger
DE112007000530A5 (de) Kopfplatte
FI7261U1 (fi) Hiomakone
DE602006019048D1 (de) EDDH enthaltende Entzunderungslösungen
FR2900477B3 (fr) Lunettes
SE0600253L (sv) Hållaranordning
EP2119010A4 (en) INTEGRATED CIRCUITS
FI7259U1 (fi) Työstökeskus
FR2899778B1 (fr) Console
SE0600721L (sv) Nyckelhållare
CN300764037S (zh) 耳机

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.